Historically, lung cancer is a disease with limited treatment options, late-diagnosis, and a limited spectrum of chemotherapies that have toxic side effects and a poor response rate, but there have been several exciting developments in recent years. In this latest instalment of ERS Vision, Professor Stephen Holgate explores recent advances in lung cancer diagnostics, changes in clinical trial design and improved standards of care, and discusses the optimistic future of lung cancer treatment.